293. What is Different When Dealing With Bacteremic Brucellosis ?
Session: Poster Abstract Session: Global Infections
Thursday, October 5, 2017
Room: Poster Hall CD
Posters
  • 293 What is Different When Dealing With Bacteremic Brucellosis.pdf (52.7 kB)
  • Background:

    Bacteremic brucellosis is an acute febrile disease often associated with digestive complaints and biological inflammatory syndrome. In this perspective, our study aimed to determine predictive factors of bacteremia in patients with brucellosis.

    Methods:

    We conducted a retrospective study including all patients hospitalized with brucellosis between 1990 and 2014.

    Results:

    We included 161 cases of brucellosis among which bacteremia was documented in 30 cases (18.6%). Mean age was of 39.6±17 years. Brucella melitensis was solely isolated. In bacteremic brucellosis, there were more fever (93.3% vs. 78%; p=0.049; HR=4), nausea (16.7% vs. 4.6%; p=0.033; HR=4.2) and splenomegaly (20% vs. 7.6%; p=0.049; HR=3). The acute form was significantly more common in bacteremic brucellosis (66.7% vs. 42%; p=0.015; HR=2.7). Bacteremic brucellosis patients had a significantly higher frequence of anemia (76.7% vs. 51.6%; p=0.013; HR=3.2) and higher C-reactive protein value (85.5±45 vs. 35±20 mg/L; p<0.001). Commonly used antimicrobial regimens consisted of rifampicin plus doxycycline given for 6 weeks in both bacteremic and non-bacteremic brucellosis (86.7% vs. 72%; p=0.1). A favorable outcome was significantly associated with bacteremic brucellosis (73.3% vs. 52%; p=0.03; HR=2.38). Multivariate analysis using logistic regression revealed that the presence of nausea (HR= 9; CI95% 14-60; p=0.002), acute form of brucellosis (HR= 4.5; CI95% 1.2-17; p=0.025) and C-reactive protein value (HR= 1.12; CI95% 1.1-1.2; p=0.02) were independent predictors of bacteremic brucellosis.

    Conclusion:

    Our study highlighted clinical and biological particularities of bacteremic brucellosis which may help clinicians to establish a prompt diagnosis and suitable treatment, two main conditions to improve patients' prognosis.

    Houda Ben Ayed, MD1, Makram Koubaa, MD2, Fatma Smaoui, MD2, Yosra Mejdoub, MD3, Tarak Ben Jemaa, MD2, Imed Maaloul, MD2, Sourour Yaich, MD3, Chakib Marrakchi, MD2 and Mounir Ben Jemaa, MD2, (1)Department of Community Health and Epidemiology, Hedi Chaker University Hospital, Sfax, Tunisia, (2)Department of Infectious Diseases, Hedi Chaker University Hospital, Sfax, Tunisia, (3)Department of Epidemiology, Hedi Chaker University Hospital, Sfax, Tunisia

    Disclosures:

    H. Ben Ayed, None

    M. Koubaa, None

    F. Smaoui, None

    Y. Mejdoub, None

    T. Ben Jemaa, None

    I. Maaloul, None

    S. Yaich, None

    C. Marrakchi, None

    M. Ben Jemaa, None

    See more of: Global Infections
    See more of: Poster Abstract Session
    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.